Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27632909 | 0.83 | ALDH1A1 (0.47) | KDM4EMAPTALDH1A1TSHRHSD17B10 | |
| SCHEMBL7134588 | 0.82 | TSHR (0.54) | KDM4EMAPTALDH1A1TSHRHSD17B10 | |
| SCHEMBL4735612 | 0.82 | ALDH1A1 (0.54) | KDM4EMAPTALDH1A1TSHRHSD17B10 | |
| SCHEMBL405123 | 0.80 | KDM4E (0.52) | KDM4EMAPTALDH1A1TSHRHSD17B10 | |
| SCHEMBL1756158 | 0.80 | FOLH1 (0.59) | KDM4EMAPTALDH1A1TSHRHPGD | |
| SCHEMBL5252886 | 0.80 | KDM4E (0.52) | KDM4EMAPTALDH1A1TSHRHSD17B10 | |
| SCHEMBL162322 | 0.80 | MAPT (0.52) | KDM4EMAPTALDH1A1TSHRHSD17B10 | |
| SCHEMBL619877 | 0.80 | ALDH1A1 (0.52) | KDM4EMAPTALDH1A1TSHRHSD17B10 | |
| SCHEMBL6555382 | 0.80 | MAPT (0.52) | KDM4EMAPTALDH1A1TSHRHSD17B10 | |
| SCHEMBL7460853 | 0.79 | KDM4E (0.42) | KDM4EMAPTALDH1A1TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001939-A1 | TETRAHYDRO-PYRANOPYRAZOLE COMPOUNDS DISPLAYING CANNABINOID MODULATING ACTIVITIES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-04 | — | — | WO | claimed |
| US-5399748-A | Derivatives of aspartic acid and glutamic acid having anticholecystokinin activity | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-03-21 | — | — | US | claimed |
| EP-0552158-B1 | DERIVATIVES OF ASPARTIC ACID AND GLUTAMIC ACID HAVING ANTI-CHOLECYSTOKININ ACTIVITY | BLACK JAMES FOUNDATION (GB) | 1994-10-12 | — | — | EP | claimed |
| EP-0552158-A1 | DERIVATIVES OF ASPARTIC ACID AND GLUTAMIC ACID HAVING ANTI-CHOLECYSTOKININ ACTIVITY. | BLACK JAMES FOUNDATION (GB) | 1993-07-28 | — | — | EP | claimed |
| WO-1992000958-A1 | DERIVATIVES OF ASPARTIC ACID AND GLUTAMIC ACID HAVING ANTI-CHOLECYSTOKININ ACTIVITY | JAMES BLACK FOUNDATION LIMITED (GB) | 1992-01-23 | — | — | WO | claimed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| WO-2007130499-A2 | ANTIVIRAL AGENTS | VIROBAY, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-5847125-A | Amino acid derivatives with anticholecystokinin activity | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-12-08 | — | — | US | disclosed |
| EP-0650476-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-03 | — | — | EP | disclosed |
| US-5399748-A | Derivatives of aspartic acid and glutamic acid having anticholecystokinin activity | JAMES BLACK FOUNDATION LIMITED (GB) | 1995-03-21 | — | — | US | disclosed |
| EP-0552158-B1 | DERIVATIVES OF ASPARTIC ACID AND GLUTAMIC ACID HAVING ANTI-CHOLECYSTOKININ ACTIVITY | BLACK JAMES FOUNDATION (GB) | 1994-10-12 | — | — | EP | disclosed |
| EP-0552158-A1 | DERIVATIVES OF ASPARTIC ACID AND GLUTAMIC ACID HAVING ANTI-CHOLECYSTOKININ ACTIVITY. | BLACK JAMES FOUNDATION (GB) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992000958-A1 | DERIVATIVES OF ASPARTIC ACID AND GLUTAMIC ACID HAVING ANTI-CHOLECYSTOKININ ACTIVITY | JAMES BLACK FOUNDATION LIMITED (GB) | 1992-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | KDM4E 4854/4885MAPT 4117/4885ALDH1A1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.